|
|
|
|
Cubist Pharmaceuticals to Present at RBC Capital Markets 2008 Healthcare Conference
- Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced that David McGirr, SVP and CFO, will present on Wednesday, December 10th at 9:00 A.M. ET at the RBC Capital Markets 2008 Healthcare Conference being held at the Westin New...
|
|
|
K-ras genotype predicts antitumor response to cetuximab in advanced colorectal - Cetuximab is effective agains
Key point: Clostridium difficile (C.difficile), the opportunistic pathogen that causes antibiotic-associated diarrhea, is more prevalent, virulent, and likely to cause death compared with 10 years ago. Finer points: CP Kelly and...
|
|
|
Effect of Dapoxetine on the Pharmacokinetics and Hemodynamic Effects of Tamsulosin in Men on a Stable Dose of
Modi, PhD, S.Kell, MD, J. Aquilina, MD and D. Rivas, MD From Clinical Pharmacology (Dr Modi) and Clinical Development (Dr Kell), ALZA Corporation, Mountain View, California, and Johnson & Johnson Pharmaceutical Research &...
|
|
|
Zealand Signs Helsinn to ?140M Deal for GLP-2 Agonist in CID
Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential 140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced ...
|
|
|
Zealand Pharma, Helsinn Healthcare sign diarrhea pact
Denmarks Zealand Pharma has tied up with Helsinn Healthcare for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist that provides a novel way to treat chemotherapy-induced diarrhea...
|
|
|
Zealand Pharma inks $177M pact for early-stage compound
Denmark's Zealand Pharma has licensed out the worldwide rights--outside of the Nordic countries--to an early-stage compound targeting chemotherapy-induced diarrhea.Helsinn gained the marketing rights to the drug as part of a package...
|
|
|
What You Should Know About Ovarian and Cervical Cancer
Fortunately, women today are well educated on the symptoms of breast cancer.Most know when something is abnormal they should quickly see a doctor. Unfortunately, the same is not always true with the other female cancers, particularly...
|
|
|
Children's Hospital Reminds Parents To Stay Alert During Holidays
The holidays are an exciting and busy time of year as parents race to finish shopping, decorating and baking.As the number of days left in the calendar year winds down, be sure to allow plenty of time in the hectic schedule for playtime...
|
|
|
Novartis Malaria Drug Safe, Effective: FDA
Data show Novartis AG's combination malaria drug Coartem appears to work and causes few serious side effects, U.S.Food and Drug Administration regulatory staff said in documents released on Monday. 'The majority of AEs (adverse events)...
|
|
|
Managing end-stage heart failure
Q: Please provide an updated review on managing end-stage canine heart failure.A: Drs. Sonya G. Gordon and Risa Roland gave an excellent lecture on managing end-stage canine heart failure and canine hospice care at the 2008 American...
|
|
|
Zealand Pharma and Helsinn Healthcare SA Sign a ,140 Million (US$176.8 Million) Partnering Agreement for ZP1
- Summary: Zealand Pharma A/S and today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday season is, for...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday season is, for...
|
|
|
Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder
British Medical Journal study finds natural, less expensive treatments are effective for Irritable Bowel Syndrome Sufferers PRINCETON, N.J., Dec.2 /PRNewswire/ -- With its feasts, travel and family gatherings, the holiday season is, for...
|
|
|
Helsinn Healthcare And Zealand Pharma Sign A Partnering Agreement For ZP1846, A Novel GLP-2 Agonist
Lugano, Switzerland - Helsinn Healthcare's Top management recently announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2)...
|
|
|
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
/PRNewswire/ -- Helsinn Healthcare's Top management today announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor...
|
|
|
Canada Pushes for At-Home Colon Cancer Screening
It might not be pleasant, but it could save your life.A new Canadian campaign advocating home screening for colorectal cancer could reduce deaths from the disease by catching it early, when it is often asymptomatic but also highly curable...
|
|
|
UPDATE 2-Data supports Novartis malaria drug -US FDA staff
By Susan Heavey WASHINGTON, Dec 1 (Reuters) - Data show Novartis AG's combination malaria drug Coartem appears to work and causes few serious side effects, U.S.Food and Drug Administration regulatory staff said in documents released on...
|
|
|
UPDATE 1-Novartis malaria drug safe, effective-US FDA staff
By Susan Heavey WASHINGTON, Dec 1 (Reuters) - Data show Novartis AG's combination malaria drug Coartem appears to work and causes few serious side effects, U.S.Food and Drug Administration regulatory staff said in documents released on...
|
|
|
Zealand Signs Helsinn to EUR140M Deal for GLP-2 Agonist in CID
By Jennifer Boggs Assistant Managing Editor Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential 140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2...
|
|
|
Zealand Signs Helsinn to ?140M Deal for GLP-2 Agonist in CID
Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential ?140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced ...
|
|
|
Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonist
- Zealand Pharma A/S and Helsinn Healthcare SA announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way...
|
|
|
Novartis malaria drug safe, effective: U.S. FDA staff
WASHINGTON (Reuters) - Data show Novartis AG's combination malaria drug Coartem appears to work and causes few serious side effects, U.S.Food and Drug Administration regulatory staff said in documents released on Monday. 'The majority...
|
|
|
Data supports Novartis malaria drug -US FDA staff
NOVARTIS-MALARIA (UPDATE 2):UPDATE 2- (Adds Novartis comment throughout, more details from documents) WASHINGTON (Reuters) - Data show Novartis (nyse: NVS - news - people ) AG's combination malaria drug Coartem appears to work and causes few...
|
|
|
HIV/AIDS Testing Campaign in Kenya Successfully Combines Diarrhea and Malaria Prevention
A campaign in Africa to prevent malaria, diarrhea and aids used a unique approach to get a large number of people to test for HIV in a short period of time.It was created by the Vestergaard-Frandsen Company, which creates products...
|
